Document Type : Original Article
Authors
1 Department of Pediatrics, Iran University of Medical Sciences, Tehran, Iran
2 General practitioner (GP), Tabriz University of Medical Sciences, Tabriz, Iran
3 General Practitioner (GP), Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Department of Anesthesiology, Iran University of Medical Science, Tehran, Iran
Abstract
Introduction: In this study, we evaluated the Seroepidemiology of T. gondii among470 pregnant women as well as association of infection with socio-demographic factors and risk factors such as age, and education was studied, which makes it a potential therapeutic option for personalized medicine. Methods: This cross sectional study was conducted among 470 pregnant women who presented to health centers from February 2013 to January 2014. Serum samples were prepared via a commercial ELISA kit (Euroimmun, Germany) for the attendance of IgG and IgM toxoplasma antibodies and the avidity of the IgG antibody based on the manufacturer’s protocol. Results: We found 34.4% of Toxoplasma IgG. Among 470 pregnant women, 166 cases positive for IgG antibodies toxoplasma were detected, showing a serum incidence of 35.31% (95% confidence interval 27.8 to 37.06%),and thirty eight (22.89%) out of 166 IgG-positive women revealed specific IgM antibodies. Conclusions: Our data showed that the prevalence of T. gondii infection is not related to age, gestational age, number of pregnancies, history of abortion, contact with soil, life in rural areas and education related to infection. as well as these findings may be of major interest for the select of the first-line anti-infection drug, and the urgent require for developing personalized medicine.
Keywords
Manakou C, Karkabouna S, et al. Realities and expectations of
pharmacogenomics and personalized medicine: impact of
translating genetic knowledge into clinical practice.
Pharmacogenomics. 2010;11(8):1149-67. doi:
10.2217/pgs.10.97 pmid: 20712531
2. Weiss L, Kim K. Toxoplasma gondii: the model apicomplexan.
Perspectives and methods. London, United Kingdom:
Academic Press; 2007.
3. Cunningham F, Leveno K, Bloom S, Hauth J, Gilstrap L,
Wenstron K. Williams's obstetrics. New York: McGraw-Hill;
2005.
4. Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical
observations. Int J Parasitol. 2009;39(8):895-901. doi:
10.1016/j.ijpara.2009.02.004 pmid: 19217908
5. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet.
2004;363(9425):1965-76. doi: 10.1016/S0140-
6736(04)16412-X pmid: 15194258
6. Dubey JP. The history of Toxoplasma gondii--the first 100
years. J Eukaryot Microbiol. 2008;55(6):467-75. doi:
10.1111/j.1550-7408.2008.00345.x pmid: 19120791
7. Youssefi MR, Sefidgar AA, Mostafazadeh A, Omran SM.
Serologic evaluation of toxoplasmosis in matrimonial women
in Babol, Iran. Pak J Biol Sci. 2007;10(9):1550-2. pmid:
19069975
8. Sharifi-Mood B, Hashemi-Shahri M, Salehi M, Naderi M,
Naser-Poor T. Seroepidemiology of Toxoplasma infection in
the pregnant women in Zahedan, Southeast of Iran. J Res
Health Sci 2011;4(2):1-3.Mostafavi S, Jalali Monfared L. Toxoplasmosis epidemiology
in Iran: a systematic review. J Isfahan Med Sch.
2012;176(30):1-15.
10. Remington JS, Klein JO, Wilson CB, Nizet V, Maldonado YA.
Infectious diseases of the fetus and newborn infant.
Philadelphia: Saunders 2006.
11. Wellington A, Oladipo O, Chimere O, Oladele T, Anunobi
CC, Soyebi K. Congenital Toxoplasmosis: A Review of its
Pathology, Immune Response and Current Treatment
Options. Sierra Leone J Biomed Res. 2009;1(1):9-20.
12. Fallah M, Rabiee S, Matini M, Taherkhani H.
Seroepidemiology of toxoplasmosis in primigravida women in
Hamadan, Islamic Republic of Iran, 2004. East Mediterr
Health J. 2008;14(1):163-71. pmid: 18557464
13. Hajsoleimani F, Ataeian A, Nourian A, Mazloomzadeh S.
Seroprevalence of Toxoplasma gondii in Pregnant Women and
Bioassay of IgM Positive Cases in Zanjan, Northwest of Iran.
Iran J Parasitol. 2012;7(2):82-6. pmid: 23109950
14. Soltan Mohammad Zadeh M, Keshavarz H, Mohebali M,
Holakouie Naieni K, Arshi S. Seroepidemiologic study of
human Toxoplasma infection in residents of Meshkin-Shahr. J
Sch Public Health Instit Public Health Res. 2003;1(4):57-72.
15. Gras L, Gilbert RE, Wallon M, Peyron F, Cortina-Borja M.
Duration of the IgM response in women acquiring Toxoplasma
gondii during pregnancy: implications for clinical practice and
cross-sectional incidence studies. Epidemiol Infect.
2004;132(3):541-8. pmid: 15188723
16. Petersen E, Vesco G, Villari S, Buffolano W. What do we know
about risk factors for infection in humans with Toxoplasma
gondii and how can we prevent infections? Zoonoses Public
Health. 2010;57(1):8-17. doi: 10.1111/j.1863-
2378.2009.01278.x pmid: 19744301
17. Robert-Gangneux F, Darde ML. Epidemiology of and
diagnostic strategies for toxoplasmosis. Clin Microbiol Rev.
2012;25(2):264-96. doi: 10.1128/CMR.05013-11 pmid:
22491772
18. Babaie J, Amiri S, Mostafavi E, Hassan N, Lotfi P, Esmaeili
Rastaghi AR, et al. Seroprevalence and risk factors for
Toxoplasma gondii infection among pregnant women in
Northeast Iran. Clin Vaccine Immunol. 2013;20(11):1771-3.
doi: 10.1128/CVI.00125-13 pmid: 24006138
19. Barbosa IR, de Carvalho Xavier Holanda CM, de Andrade-
Neto VF. Toxoplasmosis screening and risk factors amongst
pregnant females in Natal, northeastern Brazil. Trans R Soc
Trop Med Hyg. 2009;103(4):377-82. doi:
10.1016/j.trstmh.2008.11.025 pmid: 19211119
)